Literature DB >> 21063124

Validation and clinical use of the Japanese classification of colorectal carcinomatosis: benefit of surgical cytoreduction even without hyperthermic intraperitoneal chemotherapy.

Hirotoshi Kobayashi1, Masayuki Enomoto, Tetsuro Higuchi, Hiroyuki Uetake, Satoru Iida, Toshiaki Ishikawa, Megumi Ishiguro, Kenichi Sugihara.   

Abstract

BACKGROUND: This study aimed to validate an easy to use practical classification of peritoneal metastasis arising from colorectal cancer. PATIENTS AND METHODS: Data from 2,134 consecutive patients who underwent resection for colorectal cancer at a single institution were reviewed. Peritoneal metastasis was classified depending on extent into three groups (P1-P3). The macroscopic radical resection rates and survival of patients with colorectal cancer complicated with peritoneal metastasis were analyzed.
RESULTS: Of the 2,134 patients, 116 (5.4%) had peritoneal metastasis. Among them, 20 (17.2%) underwent macroscopic radical resection. Tumor location on the right side was associated with more extensive peritoneal metastasis (p = 0.010). Male gender (p = 0.0027), liver metastasis (p = 0.0021), and P3 peritoneal metastasis were independent risk factors for noncurative resection. The Cox proportional hazards model showed that gender (p = 0.031), operation period (p = 0.031), and macroscopic radical resection for colorectal cancer and peritoneal metastasis (p = 0.031) were independent prognostic factors.
CONCLUSIONS: Being female with left colon cancer complicated with P1 or P2 peritoneal metastasis is a good indicator for macroscopic radical resection if liver metastasis is absent. The present classification helped to determine surgical indication for patients with colorectal cancer complicated with synchronous peritoneal metastasis in routine clinical practice.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 21063124     DOI: 10.1159/000320460

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  13 in total

1.  Oxaliplatin and molecular-targeted drug therapies improved the overall survival in colorectal cancer patients with synchronous peritoneal carcinomatosis undergoing incomplete cytoreductive surgery.

Authors:  T Adachi; T Hinoi; H Egi; M Shimomura; H Ohdan
Journal:  Surg Today       Date:  2014-08-26       Impact factor: 2.549

2.  Oncological benefit of primary tumor resection with high tie lymph node dissection in unresectable colorectal cancer with synchronous peritoneal metastasis: a propensity score analysis of data from a multi-institute database.

Authors:  Tomohisa Furuhata; Kenji Okita; Toshihiko Nishidate; Koichi Hirata; Hirofumi Ohnishi; Hirotoshi Kobayashi; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2015-03-12       Impact factor: 3.402

3.  Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy?

Authors:  H Ishida; K Kumamoto; K Ishibashi; S Hatano; T Matsuzawa; N Okada; Y Kumagai; H Baba; N Haga
Journal:  Tech Coloproctol       Date:  2013-02-07       Impact factor: 3.781

4.  Prognostic significance of peritoneal lavage cytology in patients with colorectal cancer.

Authors:  Hirotoshi Kobayashi; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2012-02-28       Impact factor: 3.402

5.  Prognoses and treatment strategies for synchronous peritoneal dissemination of colorectal carcinoma.

Authors:  Harunobu Sato; Kunihiro Toyama; Yoshikazu Koide; Shinji Ozeki; Kouhei Hatta; Kotaro Maeda
Journal:  Surg Today       Date:  2015-10-03       Impact factor: 2.549

6.  Outcomes of surgery without HIPEC for synchronous peritoneal metastasis from colorectal cancer: data from a multi-center registry.

Authors:  Hirotoshi Kobayashi; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2012-12-13       Impact factor: 3.402

7.  Factors affecting recurrence and prognosis after R0 resection for colorectal cancer with peritoneal metastasis.

Authors:  Harunobu Sato; Koutaro Maeda; Kenjiro Kotake; Kenichi Sugihara; Hiroshi Takahashi
Journal:  J Gastroenterol       Date:  2015-09-16       Impact factor: 7.527

8.  Clinical benefit of surgery for stage IV colorectal cancer with synchronous peritoneal metastasis.

Authors:  Hirotoshi Kobayashi; Kenjiro Kotake; Kimihiko Funahashi; Kazuo Hase; Koichi Hirata; Tsuneo Iiai; Shingo Kameoka; Yukihide Kanemitsu; Koutarou Maeda; Akihiko Murata; Masayuki Ohue; Kazuo Shirouzu; Keiichi Takahashi; Toshiaki Watanabe; Hideaki Yano; Toshimasa Yatsuoka; Yojiro Hashiguchi; Kenichi Sugihara
Journal:  J Gastroenterol       Date:  2013-06-24       Impact factor: 7.527

Review 9.  Therapeutic options for peritoneal metastasis arising from colorectal cancer.

Authors:  Gabriel Glockzin; Hans J Schlitt; Pompiliu Piso
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-08-06

10.  Palliative surgery for colorectal cancer with peritoneal metastasis: a propensity-score matching analysis.

Authors:  Seon Jeong Jeong; Yong Sik Yoon; Jung Bok Lee; Jong Lyul Lee; Chan Wook Kim; In Ja Park; Seok Byung Lim; Chang Sik Yu; Jin Cheon Kim
Journal:  Surg Today       Date:  2016-08-22       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.